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Abstract
Objective: Enterovirus 71 (EV71) is causing life-threatening outbreaks in tropical Asia. In Taiwan and other tropical Asian
countries, although nationwide EV71 epidemics occur cyclically, age-specific incidence rates of EV71 infections that are
critical to estimate disease burden and design vaccine trials are not clear. A nationwide EV71 epidemic occurred in 2008–09
in Taiwan, which provided a unique opportunity to estimate age-specific incidence rates of EV71 infections.
Study Design: We prospectively recruited 749 healthy neonates and conducted follow-ups from June 2006 to December
2009. Sera were obtained from participants at 0, 6, 12, 24, and 36 months of age for measuring EV71 neutralizing antibody
titers. If the participants developed suspected enterovirus illnesses, throat swabs were collected for virus isolation.
Results: We detected 28 EV71 infections including 20 symptomatic and 8 asymptomatic infections. Age-specific incidence
rates of EV71 infection increased from 1.71 per 100 person-years at 0–6 months of age to 4.09, 5.74, and 4.97 per 100
person-years at 7–12, 13–24, and 25–36 months of age, respectively. Cumulative incidence rate was 15.15 per 100 persons
by 36 months of age, respectively.
Conclusions: Risk of EV71 infections in Taiwan increased after 6 months of age during EV71 epidemics. The cumulative
incidence rate was 15% by 36 months of age, and 29% of EV71 infections were asymptomatic in young children.
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Introduction
Enterovirus 71 (EV71) was first isolated in California, USA, in
1969. Since then, EV71 has been identified globally. The clinical
spectrum of EV71 infection ranges from asymptomatic infection,
to mild hand-foot-mouth disease (HFMD), and severe cases with
central nervous system (CNS), and cardiopulmonary involvement
[1,2]. Recent studies have further demonstrated that CNS-
complicated EV71 infections could cause long-term cognitive
and motor deficits [3,4]. Globally, two patterns of EV71 outbreaks
have been reported: small-scale outbreaks with few CNS-
complicated cases and deaths, and large-scale outbreaks with
frequent CNS-complicated cases and deaths [1]. The latter pattern
occurred in Bulgaria, with 44 deaths in 1975 [5]; in Hungary, with
45 deaths in 1978 [6]; in Malaysia, with 29 deaths in 1997 [7]; in
Taiwan, with 78 deaths in 1998 [8]; in Singapore, with 5 deaths in
2000 [9]; and recently in China, with more than 100 deaths in
2007, 2008, and 2009 [10–12]. Since the 1998 epidemic, EV71
has continued to cause nationwide epidemics again in 2000–2001,
2004–2005, and 2008–2009 in Taiwan [12–22].
No antiviral against EV71 is currently available, so development
of EV71 vaccines has become a national priority in Taiwan and
China, and several organizations in Asia are planning clinical trials
of EV71 vaccines [12]. To design clinical trials of EV71 vaccines,
age-specific incidence rates of EV71 infections are required to
identify target populations, estimate disease burdens, select
endpoints of clinical efficacy, and estimate sample size. Taiwan
has had a national surveillance system for severe enterovirus
infections since 1998. Age-specific incidence rates of EV71-related
severe infections during the 1998 epidemic have been estimated to
be 27.3, 37.1, 30.0, and 23.1 per 100,000 for children aged ,6, 6–
11, 12–23, and 24–35 months, respectively [23], which are too low
to be a suitable clinical endpoint. Alternatively, EV71-related mild
infections such as herpangina and HFMD could be suitable
clinical endpoints; but their age-specific incidence rates are not
available in Taiwan. We initiated a longitudinal cohort study in
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young children in northern Taiwan.
Methods
Ethics statement
Institutional review board approval was obtained from Chang
Gung Memorial Hospital (CGMH) following the Helsinki
Declaration; and written informed consent was obtained from all
mothers of participating infants.
Study populations
Pregnant women having prenatal exams in CGMH were
invited to participate in the study starting in June 2006. Sera were
obtained from participating pregnant women and their children
for measuring EV71 neutralizing antibody titers in the following
schedule: pregnant women immediately before delivery; neonates
at birth (cord blood); and infants at 6, 12, 24, and 36 months of
age. About 20–30 participants were recruited every month.
Parents were educated to contact study staff when their children
developed suspected enterovirus illnesses (herpangina or HFMD).
During enterovirus seasons, study staff actively contacted parents
about suspected enterovirus illnesses by e-mail, telephone or text
message. If the participating children developed suspected
enterovirus illnesses, throat swabs were collected from these
participating children for virus isolation. In previous studies,
throat swabs were more sensitive than rectal swabs or feces for
isolating EV71 viruses in acute EV71 cases [12]. Occasionally,
pediatricians also collected throat swabs from the participating
children who developed non-specific febrile illness for virus
isolation during enterovirus seasons. We chose CGMH as a study
site because it has large obstetric and pediatric populations and
serves residents from both rural and urban areas in northern
Taiwan [14,22–24]. In additional to the infant cohort study,
clinical samples (throat swabs, rectal swabs, or stool samples) are
routinely collected for virus isolation from hospitalized pediatric
patients with suspected enterovirus infections (herpangina,
HFMD, or non-specific febrile illness) in CGMH. Monthly
distribution of EV71 isolation in pediatric inpatients the study
hospital is based on the routine statistics and is anonymized. This
information was used to decide EV71 seasons for data analysis.
Data related to serum EV71 antibody titers in pregnant women,
neonates and 6-month-old infants have been published previously
[24] and this report focused on incidence rate of EV71 infections
in the first three years of life.
Clinical and laboratory definitions
In this study, evidence of herpangina included oral ulcerations
on anterior tonsillar pillars, soft palate, buccal mucosa, or uvula.
Evidence of HFMD included oral ulcers on the tongue and
buccal mucosa, and a vesicular rash on the hands, feet, knees, or
buttocks. Nonspecific febrile illness was defined as a rectal
temperature greater than 38uC without other symptoms.
Laboratory evidence of EV71 infection was defined as the
isolation of EV71 from a throat swab; or a $4-fold rise or
seroconversion in EV71 neutralizing antibody titers in paired sera
samples. Asymptomatic EV71 infection was defined as a
seroconversion in EV71 neutralizing antibody titers in paired
sera samples without display of clinical symptoms during the
period of collection of paired sera.
Virological analysis
Samples were inoculated into human embryonic fibroblast,
LLC-MK2, HEp-2, and rhabdomyosarcoma cell cultures. When
enteroviral cytopathic effect involved more than 50% of the cell
monolayer, cells were scraped and subjected to indirect fluorescent
antibody staining with enterovirus monoclonal antibodies [25].
Serologic assays
Laboratory methods for measuring EV71 serum neutralizing
antibody titers followed standard protocols [26–27]. Twofold
serially diluted sera (1:8–1:512) and a virus working solution
containing 100 TCID50 of EV71 strain E59-TW-2002 (B4
genotype) were mixed on 96-well microplates and incubated with
rhabdomyosarcoma cells. A cytopathic effect was observed in a
monitor linked with an inverted microscope after an incubation
period of 4 to 5 days. The neutralization titers were read as the
highest dilution that could result in a 50% reduction in the
cytopathic effect. Each test sample was run simultaneously with
cell control, serum control, and virus back titration. The starting
dilution was 1:8; the cutoff level of seropositivity was set at 8. For
deciding serostatus (positive or negative), sera were tested only at
1:8.
Statistical analysis
Since no EV71 infection was detected in our study cohort in
2006 and 2007 [22], observation time (person-months) for
participants who returned for follow up during 2008 and 2009
were summed and converted to person-years to calculate age-
specific incidence rates and 95% confidence interval (95% CI)
based on the Poisson distribution [27]. Cumulative incidence
rates were calculated for participants who returned for follow up;
and 95% CIs of cumulative incidence rates were calculated
based on the binominal exact distribution. Neutralization
antibody titers were log-transformed to calculate the GMT and
95% CI. The statistical association between two nominal or
ordinal variables was tested by the x
2 test, Fisher’s exact test, or
the Mantel-Haenszel x
2 test for trend, as appropriate. All
statistical analyses were performed using Microsoft Excel
(Microsoft, Redmond, WA, USA) or SAS (SAS Institutes, Cary,
NC, USA).
Author Summary
Enterovirus 71 (EV71) was first isolated in California, USA, in
1969. Since then, EV71 has been identified globally.
Recently, EV71 caused several life-threatening outbreaks
in young children in tropical Asia. Development of EV71
vaccines becomes national priority in several Asia coun-
tries including Taiwan. To design clinical trials of EV71
vaccines, age-specific incidence rates of EV71 infections
are required to identify target populations, estimate
disease burdens, select endpoints of clinical efficacy, and
estimate sample size. In Taiwan, nationwide EV71 epidem-
ics occurred every 3–4 years but age-specific incidences of
EV71 infection are not available. In 2006, we initiated a
prospective cohort study in northern Taiwan to recruit
neonates and follow up them. In 2008–09, a nationwide
EV71 epidemic occurred and we found that age-specific
incidence rates of EV71 infection increased from 1.71 per
100 person-years at 0–6 months of age to 4.09, 5.74, and
4.97 per 100 person-years at 7–12, 13–24, and 25–36
months of age, respectively. The cumulative incidence rate
was 15% by 36 months of age, and 29% of EV71 infections
were asymptomatic in young children. These findings
would be helpful to development of EV71 vaccines in
Taiwan and other Asian tropical countries.
Incidence Rate of Enterovirus 71 Infection, Taiwan
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Enterovirus Surveillance
In CGMH, clinical samples are routinely collected for virus
isolation from hospitalized pediatric patients with suspected
enterovirus infections. From 2007 to 2009, 4691 pediatric
inpatients were tested for enterovirus cultures and the enterovirus
isolation rates in these three years were 14% (207/1475), 21%
(420/1969), and 15% (181/1247), respectively. EV71 was isolated
from 123 inpatients, including 5 cases in 2007, 104 cases in 2008,
and 14 cases in 2009. Only 5 sporadic EV71 inpatients were
detected in 2007, all in the middle of the year. In January 2008,
EV71 inpatients began being detected again, with the numbers
growing rapidly before peaking in June of that year and
disappearing after July 2009 (Fig. 1). Overall, the pattern was
consistent with that observed in the prospective cohort study.
Laboratory Diagnosis
Between June 2006 to June 2009, 749 neonates were recruited
into the cohort study. In 2008–09, 124 herpangina and 9 HFMD
cases were detected and 128 of them provided clinical samples
(throat swabs or serum) for laboratory diagnosis. In addition, 20
children developing non-specific illnesses including fever, upper
respiratory illness, and viral exanthema also provided clinical
samples for laboratory diagnosis. Among 118 symptomatic
children providing throat swabs for virus culture, 40 (34%) had
enterovirus isolated and 5 were EV71. In total, 20 symptomatic
EV71 infections were detected in the children’s cohort study,
including 5 herpangina cases, 6 HFMD cases, and 9 cases with the
non-specific illnesses (Table 1). None of the EV71 cases identified
in the cohort developed complications. Among the 20 symptom-
atic EV71 infections, all developed seroconversion and 9 of them
provided throat swabs for virus culture in acute phase. In these 9
cases, EV71 and cytomegalovirus were isolated from 5 and 2 cases,
respectively. Overall, the virus isolation rate was significantly lower
than the seroconversion rates for detecting EV71 infections (4.2%
vs. 16.7%, P,0.01, Fisher’s exact test). In addition, 8 asymptom-
atic EV71 infections were detected by seroconversion.
Incidence Rate
Between January 2008 and December 2009, 307, 391, 294, and
66 children returned for follow up and serum collections at 6, 12,
24, and 36 months of age, respectively. Overall, the follow-up rates
at 6, 12, 24 and 36 months of age were 73%, 67%, 55% and 51%,
respectively. The major reason for loss of follow-up was refusal of
providing blood samples. As shown in Table 2, age-specific
incidence rates of EV71 infections in young children increased
gradually from 1.71 per 100 person-years at 0–6 months of age to
4.09, 5.74, and 4.97 per 100 person-years at 7–12, 13–24, and 25–
36 months of age, respectively. Table 3 shows the cumulative
incidence rates, which increased from 0.65% (95% CI, 0.08%,
2.33%) at 6 months of age to 6.46% (95% CI, 3.94%, 9.91%) and
15.15 (95% CI, 7.51%, 26.1%) at 24 and 36 months of age,
respectively.
Two children who acquired EV71 infections before 6 months of
age were both asymptomatic and one of them had neutralizing
antibody titer in cord blood (antibody titer 16). Among 7 children
who acquired EV71 infections at 7–12 months of age, 2 were
asymptomatic and 5 were symptomatic. The 2 asymptomatic cases
both had neutralizing antibody titer in cord bloods and their
maternal antibodies declined to undetectable level at 6 months of
age. In contrast, only 2 of the 5 symptomatic cases had detectable
EV71 neutralizing antibody in cord blood and their maternal
antibodies also declined to undetectable level at 6 months of age.
The 2 symptomatic cases with detectable maternal antibody in
cord blood were infected at 7 and 9 months of age and the 3
symptomatic cases without detectable maternal antibody in cord
blood were infected at 7, 8 and 9 months of age.
Discussion
EV71 continues to cause disease with the potential for life-
threatening infections in Asian children. Development of EV71
vaccines has become a national priority in Taiwan and China. To
design clinical trials of EV71 vaccines, age-specific incidence rates
of EV71 infections are required to identify target populations and
select study endpoints. In this study, risk of EV71 infections greatly
increased after 6 months of age during EV71 epidemics, which is
consistent with national surveillance data of severe EV71
infections and decline of maternal antibody by 6 months of age
[23–24]. Furthermore, the cumulative incidence rate in young
children was about 15% by 36 months of age after follow-up for 2
years, which is consistent with the results of seroprevalence studies
conducted after the 1998 epidemic [23,28]. The follow-up rate by
Figure 1. Enterovirus 71 isolation in pediatric inpatients in Chang-Gung Memorial Hospital, Taiwan, 2007–2009.
doi:10.1371/journal.pntd.0001476.g001
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reason for loss of follow-up was refusal of providing blood samples.
Meanwhile, 17 (61%) of the 28 EV71-infected children continue to
return for follow-up. Overall, follow-up rates in EV71-infected and
uninfected children differed slightly. Therefore, the substantial loss
of follow-up in our study may not cause significant bias in
calculation of incidence. However, our cohort study was
conducted in northern Taiwan and more severe EV71 cases were
reported in southern Taiwan than in northern Taiwan during the
2008–2009 epidemic. It should be cautious about extrapolating
finding of this study to whole Taiwan. In addition, EV71
epidemics occurred every 3–4 years in the past 10 years in
Taiwan, which may greatly affect the estimation of age-specific
incidence rates.
In addition, in our prospective cohort 29% of EV71 infections
in young children were asymptomatic, 32% had non-specific
illness, and 39% developed herpangina/HFMD. In a retrospective
study conducted in Taiwan in 1999, Chang et al. found that 29%
of 484 EV71-seropositive children ,6 years of age developed
herpangina/HFMD and 71% were asymptomatic [23]. In a
prospective hospital-based case-finding study conducted in a
medical center in 2001–02, 6% of 183 EV71 infections in children
,18 years of age were asymptomatic, 13% developed non-specific
illnesses, and 71% developed herpangina/HFMD [14]. It is hard
to compare our study with the other two studies due to differences
in study designs, age groups, laboratory diagnosis, and genotypes
of circulating EV71. Overall, the retrospective study could not
differentiate EV71 infections with non-specific illnesses from
asymptomatic EV71 infections and the prospective hospital-based
case-finding study would underestimate the proportion of
asymptomatic infections. Therefore, our prospective infant cohort
study is more likely to reflect occurrences of EV71 infections in the
community.
Due to small sample size, our prospective study could not detect
any complicated EV71 infections. In the prospective hospital-
based case-finding study, 21% of 183 EV71 infections in children
,18 years of age developed neurological complications such as
meningitis and encephalitis [14]. Based on national severe
enterovirus surveillance with virus isolation and two cross-sectional
serosurveys, Lu et al. estimated that 130617 Taiwanese children
aged ,3 years were infected with EV71 infections in 1998 and
that 273 (0.21%) of these infected children developed neurological
complications [28]. Overall, the prospective hospital-based case-
finding study would overestimate the proportion of EV71
infections with neurological complications and the national
surveillance data would underestimate the proportion of EV71
infections with neurological complications.
Interestingly, we found that the 2 children who acquired EV71
infections before 6 months of age were both asymptomatic and
their EV71 neutralizing antibody titers at birth, 6 and 12 months
of age were 16, 256 and 32, and ,8, 128 and no serum collected
at 12 months of age, respectively. Chang et al. [23] also found that
children ,6 months of age were more likely to develop
asymptomatic EV71 infections than children .6 months of age.
These observations may indicate that maternal antibody may
provide protection against symptomatic EV71 infections in young
infants even though EV71-specific maternal antibody may have
declined to undetectable levels in these young infants.
Current standard methods for laboratory diagnosis of EV71
infections include virus isolation and serum neutralizing antibody
Table 1. Laboratory diagnosis of symptomatic EV71 infections in young children, northern Taiwan, 2008–2009.
Clinical symptoms No. of cases Diagnosis of EV71 infections by different assays
Virus isolation
n/N (%)
Serology
n/N (%)
Combined
n/N (%)
Herpangina 124 2/100 (2.0) 5/93 (5.4) 5/119 (4.2)
HFMD 9 3/6 (50) 6/9 (67) 6/9 (67)
Other
* 20 0/12 ( 0) 9/18 (50) 9/20 (50)
Total 153 5/118 (4.2) 20/120 (17) 20/148 (16)
HFMD: hand-foot-mouth disease.
*Including febrile illness, upper respiratory illness, and viral exanthema.
doi:10.1371/journal.pntd.0001476.t001
Table 2. Age-specific incidence rates of enterovirus 71 infection in northern Taiwan, 2008–09.
Age
(months)
No. of persons (person-
month) followed No. of infections
Incidence rate
#
(95% CI
$)
Symptomatic Asymptomatic* Total
0–6 307 (1407) 0 2 2 1.71 (0.21, 6.16)
7–12 391 (2052) 5 2 7 4.09 (1.65, 8.43)
13–24 294 (3343) 13 3 16 5.74 (3.28, 9.33)
25–36 66 (724) 2 1 3 4.97 (1.03, 14.53)
Total 20 8 28
*Asymptomatic infection is identified based on seroconversion of EV71 neutralizing antibody in scheduled blood samples.
#per 100 person-years.
$95% confidence interval calculated based on the Poisson distribution.
doi:10.1371/journal.pntd.0001476.t002
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izing antibody testing ($4-fold rise) was more sensitive than virus
isolation for detecting EV71 infections [12], which was consistent
with the finding of our infant cohort study. However, the serum
neutralizing antibody testing needs to collect paired sera, which
are not always available. Several studies have found that serum
IgM tests based on single clinical specimen were more sensitive
than virus isolation for detecting EV71 infections but had a major
drawback of high false positives, especially for patients infected
with Coxsackievirus A16 [29,30]. In addition, molecular tests
based on single clinical specimen were also more sensitive than
virus isolation for detecting EV71 infections but had a major
limitation of high cost [31–33]. Our cohort study collected serial
sera to detect EV71 infections and would also be more sensitive
than molecular tests based on a single clinical specimen. Overall,
enterovirus surveillance systems based only on virus isolation for
detecting EV71 infections would significantly underestimate
disease burdens of EV71 infections [7–9]. However, after
introducing vaccines, vaccinated children would possess EV71
antibodies which would confound serological diagnosis of EV71
infection so it would be necessary to detect and serotype
enteroviruses using virus isolation and molecular methods.
Overall, harmonized and integrated laboratory diagnosis methods
are urgently needed to make national enterovirus surveillance data
comparable [12].
Like poliomyelitis viruses, vaccination would be the most cost-
effective intervention to prevent EV71-related diseases in endemic
countries. In Taiwan, the target population of EV71 vaccines has
been identified to be infants ,6 months of age [23,24]. Our
prospective infant cohort study has found that EV71-related
HFMD/herpangina is a suitable endpoint of vaccine efficacy trials
in Taiwan. In addition, the cumulative incidence rate of EV71
infections during an EV71 epidemic was about 15% by 36 months
of age, and 29% of EV71 infections were asymptomatic in young
children, that are critical for designing vaccine clinical trials.
Several organizations are planning clinical trials of EV71 vaccines
in Asia; and EV71 vaccines could be available in the near future
[12]. To successfully introduce EV71 vaccines in epidemic areas,
each country needs to well characterize its EV71 epidemiology
[34,35]. Our prospective infant cohort study would be helpful to
other countries for understanding their EV71 epidemiology.
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